Patel Chem Specialities Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 3,316,800 (47%) | — | ₹2,786 Cr |
| NII (HNI) | — | 998,400 (14%) | — | ₹839 Cr |
| Retail | — | 2,331,200 (33%) | — | ₹1,958 Cr |
| Market Maker | — | 353,600 (5%) | — | ₹30 Cr |
| Σ Total | — | 7,000,000 (100%) | — | ₹58,800 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,600 | ₹134,400 |
| Retail (Max) | 13 | 20,800 | ₹1,747,200 |
| S-HNI (Min) | 14 | 22,400 | ₹1,881,600 |
| B-HNI (Min) | 67 | 107,200 | ₹9,004,800 |
Financial Statements Amount In Crore
| Metric | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 106 | 83 | 70 |
| EBITDA | 16 | 12 | 6 |
| Profit After Tax | 11 | 8 | 3 |
| Net Worth | 35 | 20 | 12 |
| Total Assets | 65 | 47 | 37 |
| Reserves & Surplus | 18 | 19 | 11 |
| Total Borrowing | 15 | 15 | 12 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Funding capital expenditure requirement of the Company – 43.15
- 2 General corporate purposes – 8.40
Company Overview
Incorporated in 2008, Patel Chem Specialities Limited (PCSL) is engaged in the manufacturing and exporting pharmaceutical excipients and specialty chemicals.
The company manufactures various essential chemicals used in pharmaceuticals, food, cosmetics, and industrial applications, serving as binders, disintegrants, thickeners, stabilizers, and gelling agents across industries.
The company’s manufacturing facilities in Vatva, Ahmedabad, and Talod, Himmatnagar, follow strict quality control standards, ensuring bulk production of chemicals that meet international certifications like US-DMF and GMP.
The company’s manufacturing facility covers 7,000 square yards, with a capacity of over 7,200 MT annually for pharmaceutical excipients, featuring departments for storage, production, R&D, quality control, packaging, and warehousing.
The company has expanded globally, serving East Asia, Europe, the Middle East, North America, and Southeast Asia, delivering high-quality products that meet international standards to lead the chemical industry.
Product Portfolio:
- Rheollose® (Sodium Carboxymethyl Cellulose): A cellulose gum used as a thickening and stabilizing agent in various applications.
- Disolwell® (Croscarmellose Sodium): A super disintegrant used in oral pharmaceutical formulations to enhance tablet disintegration.
- Swellcal® (Calcium Carboxymethyl Cellulose): Used as a super disintegrant in pharmaceutical applications.
- AmyloTab™ (Pregelatinized Starch): Used in tablet formulations to aid in the disintegration and dissolution processes.
As of March 31, 2025, the company has a total strength of 136 employees.